Anseris Farma is part of a group with synergistic business units. Anseris Farma as such is the actual pharmaceutical company, based in Milan. To his credit he has an international patent (Biocysan) and holds 3 AICs (Farganesse, Fixodin, Tocalfa). Overall, it currently markets 28 product references while one of the above AICs is currently marketed by a third party partner. A second business unit deals with the wholesale distribution of drugs. Located in Campania, in the province of Avellino, it has all the authorizations for the transport and storage of medicines (Law 219/2006). Anseris Farma also has a partnership in 4 pharmacies. This allows a direct knowledge of the final market and a full understanding of the users' needs. Anseris Farma markets 28 different references. The products cover various therapeutic areas (andrology, vascular surgery, phlebology, nephrology, neurology, neuropsychiatry, pulmonology, proctology, urology, gynecology, gastro-enterology, otolaryngology, ophthalmology). Anseris Farma also holds 1 other marketing authorization currently marketed by another pharmaceutical company. The ownership of the "Fargan esse" brand, distributed until recently by the company Inuvance and which is now an integral part of the Anseris Farma product portfolio, completes the product portfolio. In the following two years, the product portfolio will be further enriched with the launch of new product references. Anseris Farma is present throughout the Italian territory with a network of over 40 scientific representatives and is further strengthening the territorial coverage of the sales structure. The company has developed relationships with over 15 thousand doctors, of which about 50% are specialists. In the years 2017-2018 she participated in various congresses and seminars of a scientific nature and is active in promoting studies and research in the medical field. In Switzerland it has also set up a company that has the task of distributing and marketing products abroad and has acquired, in this sense, the necessary authorizations (from Swissmedic, equivalent of the Italian Ministry of Health) to be able to operate in the EU and non-EU areas.